Company	Investors	Use Of Proceeds
Proclara Biosciences; Cambridge, Massachusetts	Prior investors led a $47m Series E round with participation from new investors, including Merieux Developpement. Proclara, formerly known as NeuroPhage Pharmaceuticals, has raised more than $110m to date, including a $17m Series D round in 2014. (Also see " BioNotebook: Offerings slow on market woes, others raise venture cash " - Scrip, 29 March, 2014.)	Proclara recently initiated a Phase Ib clinical trial for lead drug candidate NPT088 in Alzheimer’s disease, but its Series E round also will support preclinical research under its General Amyloid Interaction Motif (GAIM) platform, which allows for the targeting of multiple misfolded proteins in a single therapy to treat multi-factorial diseases. Proclara recently completed a Phase Ia trial in 40 health volunteers. A successful multi-dose Phase Ib study will support Phase II/III studies in Alzheimer’s and Parkinson’s diseases.
Inflazome; Dublin, Ireland	Novartis Venture Funds and Fountain Healthcare Partners led a Series A round that will total up to €15m ($17m).	Inflazome is developing inhibitors of the inflammasome, which regulates innate immune response in many diseases. Inflazome CEO and Co-Founder Matt Cooper said in a statement that “inflammasome activation is now implicated in many diseases driven by chronic inflammation, from Parkinson’s to asthma,” for which current therapies are inadequate.
Advantagene Inc.; Auburndale, Massachusetts	A private placement of Series A convertible preferred stock generated $14.2m. The company previously raised $2.2m in a late 2015 convertible debt financing.	Advantagene will use the funding to develop its Gene Mediated Cytotoxic Immunotherapy (GMCI) platform, including initiation of a Phase III clinical trial for lead product candidate ProstAtak in the treatment of newly diagnosed, localized prostate cancer for patients receiving radiation therapy; completion of a Phase IIb trial with localized prostate cancer patients who are undergoing active surveillance; clinical activities in brain, lung and pancreatic cancer; and development of commercial manufacturing capabilities.
AnTolRx Inc.; Cambridge, Massachusetts (ST)	AnTolRx raised $4m in its Series A financing led by Pfizer Inc., which was joined by Orion Equity Partners and the Juvenile Diabetes Research Foundation (JDRF).	Proceeds will fund the company over the next two years as AnTolRx works on developing antigen-specific targeted nanoparticle tolerance therapeutics (TNTT) to treat immune disorders. The technology comes from the lab of Francisco Quintana at Brigham and Women's Hospital and a professor at Harvard Medical School. AnTolRx's lead program in Type I diabetes is designed to selectively target pathogenic T cells via the delivery of both a self-antigen and an endogenous tolerogenic molecule, which induces an anti-inflammatory phenotype. Pfizer has an exclusive option to in-license the preclinical compound upon achievement of certain milestones.
Avitide Inc.; Lebanon, New Hampshire	Mithril Capital Management LLC led a Series D round, but the amount of money that Avitide raised was not disclosed. Avitide’s Series C round totaled $7.6m. (Also see "Avitide Raises Funds For “On-Demand” Affinity Processing" - Scrip, 15 September, 2015.)	The company develops novel affinity purification solutions used by the biopharmaceutical industry to manufacture therapeutics, including enzymes, novel scaffolds, multi-specific antibodies and vaccines. Avitide claims that its simplified protein purification process helps speed up biopharma companies’ bioprocess development timelines, reduce program risk, improve drug performance, achieve greater predictability and lower manufacturing costs. Avitide chairman and co-founder Tillman Gerngross is CEO and co-founder of the private, profitable antibody discovery firm and frequent big pharma partner Adimab LLC. (Also see "Private Adimab Breaks $1 Billion Valuation, Offers VCs Liquidity Through $100 Million Secondary" - Scrip, 6 February, 2015.)
Kleo Pharmaceuticals Inc.; New Haven, Connecticut (ST)	Kleo raised an undisclosed amount in its Series A round from Biohaven Pharmaceutical Holding Co. Ltd.; Kleo and Biohaven also entered into a clinical development master services agreement. Like Kleo, Biohaven has licensed assets from Yale University. Yale also is one of Biohaven’s investors.	Kleo was formed last year by Yale’s David Spiegel around intellectual property licensed from Yale concurrent with the Series A. The company is developing antibody recruiting molecules (ARMs) and synthetic antibody mimics (SyAMs) in an effort to activate a patient's immune system to fight off cancer and infectious diseases. Kleo says that its small molecule ARMs and SyAMs mimic the functionality of large molecules, but are lighter and easier to produce than biologics. Series A proceeds will fund pipeline development.

VC Roundup: Relay Raises $57m To Seek Drug Targets Among Proteins In Motion

More from Business

More from Scrip